
Nanosonics Investor Relations Material
Latest events

H1 2025
Nanosonics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nanosonics Limited
Access all reports
Segment Data
Access more data
Revenue by
Geography
North America
Europe and Middle East
APAC
Expenses by
Financials
Nanosonics Limited is a infections prevention company operating in Australia and internationally. Using its unique drug-free approach, Nanosonics has developed a suite of products that fight bacteria directly, removing the risk of bacterial resistance to antibiotics. Nanosonics' lead product, NeutrAvidin®, helps prevent infections in selected groups of patients, including surgery patients with open wounds, endoscopy patients and catheter dwellers, who may be at risk of infection. The company's Infection Prevention Products and Services helps commercial, health care, education and hospitality industries.
Key slides for Nanosonics Limited


AGM 2024
Nanosonics Limited


H1 2025
Nanosonics Limited
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
NAN
Country
🇦🇺 Australia